Home › Research › Biomarkers
Association of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders
Agathe Vrillon, Salvatore Spina, Jhony Alejandro Mejía‐Perez, Tia LaMore, Claire Yballa, David N. Soleimani‐Meigooni, Ganna Blazhenets, Adam L. Boxer et al.. Neurology, 2026-02-02
Topic: Brain proteins, microglia and lab models
Plain-language summary
's ≥ 0.75). Both markers identified Braak stage V-VI levels with similarly high performance (entorhinal SUVR, area under the curve [AUC] = 0.92 [95% CI 0.91-0.93]; temporal meta-ROI SUVR, AUC = 0.91 [95% CI 0.90-0.92]; plasma p-tau217, AUC = 0.90 [95% CI 0.89-0.91]), but PET outperformed plasma p-tau217 in identifying high/intermediate ADNCs (entorhinal ROI, AUC = 0.94 [95% CI 0.94-0.95]; temporal meta-ROI AUC = 0.94 [95% CI 0.94-0.95]; plasma p-tau217, AUC = 0.89 [95% CI 0.88-0.90]). Flortaucipir-PET and plasma p-tau217 both displayed strong specificity for primary AD neuropathologic diagnosis but limited sensitivity for early tau co-pathology in non-AD diagnoses.
What this study adds
Evidence grade: Moderate
The record lists 56 participants. Both flortaucipir-PET and plasma p-tau217 identified advanced Braak stages with similarly high performance, but PET was better at identifying high or intermediate Alzheimer's neuropathologic change. Reported effect size: AUC = 0.91; AUC = 0.90; AUC = 0.94.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vrillon, A., Spina, S., Mejía‐Perez, J. A., LaMore, T., Yballa, C., Soleimani‐Meigooni, D. N., et al. (2026). Association of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders. Neurology. https://doi.org/10.1212/wnl.0000000000214576
Vancouver
Vrillon A, Spina S, Mejía‐Perez JA, LaMore T, Yballa C, Soleimani‐Meigooni DN, et al. Association of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders. Neurology. 2026. doi:10.1212/wnl.0000000000214576. PMID: 41628396.
BibTeX
@article{vrillon2026-41628396,
author = {Vrillon, Agathe and Spina, Salvatore and Mejía‐Perez, Jhony Alejandro and LaMore, Tia and Yballa, Claire and Soleimani‐Meigooni, David N. and Blazhenets, Ganna and Boxer, Adam L. and others},
title = {{Association of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000214576},
pmid = {41628396},
url = {https://doi.org/10.1212/wnl.0000000000214576}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Both markers identified Braak stage V-VI levels with similarly high performance (entorhinal SUVR, area under the curve [AUC] = 0.92 [95% CI 0.91-0.93]; temporal meta-ROI SUVR, AUC = 0.91 [95% CI 0.90-0.92]; plasma p-tau217, AUC = 0.90 [95% CI 0.89-0.91]), but PET outperformed plasma p-tau217 in identifying high/intermediate ADNCs (entorhinal ROI, AUC = 0.94 [95% CI 0.94-0.95]; temporal meta-ROI AUC = 0.94 [95% CI 0.94-0.95]; plasma p-tau217, AUC = 0.89 [95% CI 0.88-0.90]).
- Flortaucipir-PET and plasma p-tau217 both displayed strong specificity for primary AD neuropathologic diagnosis but limited sensitivity for early tau co-pathology in non-AD diagnoses.
Why it matters
Both flortaucipir-PET and plasma p-tau217 identified advanced Braak stages with similarly high performance, but PET was better at identifying high or intermediate Alzheimer's neuropathologic change. Both markers were specific for primary Alzheimer's diagnosis but had limited sensitivity for early tau co-pathology in non-Alzheimer's diagnoses.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants56
- Effect sizeAUC = 0.91; AUC = 0.90; AUC = 0.94
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 56 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 47.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Renaud La Joie: h-index 73 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Berkeley: institution h-index 2,012 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41628396) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.